SynthesisEye (London, England)2026
Photobiomodulation therapy for children's eye and vision conditions.
Synthesis in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhotobiomodulation (PBM) is a non-invasive, light-based technology that stimulates cellular mechanisms, with therapeutic effect on a variety of medical conditions. Wavelengths of light are absorbed by intracellular photoreceptors, resulting in the activation of signalling pathways that culminate in biological changes within the cell. PBM treatment has been reported for a range of eye/vision conditions, mostly in adults.
objectivesWe carried out a scoping review of the published literature and collated reported uses of PBM for eye/vision/lid/orbital conditions in children and young people. ELIGIBILITY CRITERIA: We developed a comprehensive Ovid Medline, Ovid Embase and Cochrane Library search strategy. We included primary research articles written in English reporting an age range from 0 to 18 years. Ocular, vision, lid, or orbital conditions treated with PBMT, low light therapy, or intense pulsed light therapy (400-1100 nm spectral range) were included. Case reports, meta-analyses, systematic reviews, and studies using photodynamic therapy, cross-linking, or optogenetics were excluded. SOURCES OF EVIDENCE: We used Covidence Systematic Review Software for de-duplication and screening of titles and abstracts, using a pre-specified screening tool. CHARTING
methodsWe developed and used a data extraction tool in Covidence. Two reviewers (AF and CH) independently screened and extracted data, with disagreements resolved by discussion and senior-author adjudication where consensus could not be reached.
resultsOf 5081 identified studies, 45 were included. The majority focused on myopia control, reporting reductions in axial elongation, some noted rebound effects upon cessation. Amblyopia, retinopathy of prematurity, meibomian gland dysfunction, chalazion, concussion, and visual fatigue were also investigated. Most studies were randomised controlled trials, with China as the predominant investigating region. PBMT demonstrated potential benefits across various conditions with a favourable safety profile. DISCUSSION: PBMT may have a role in the management of childhood eye conditions, particularly myopia and blepharitis. It appears generally safe, with transient adverse effects such as mild photophobia and dry eye.
conclusionsFurther research is needed to optimise protocols and assess sustained efficacy and safety for widespread clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.